ESC: Cytokinetics delves deeper on ‘huge’ Myqorzo readout, fueling cardiomyopathy expansion bid

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' cardiac myosin inhibitor, Myqorzo, is the first to demonstrate significant, clinically meaningful benefits in patients with a rare heart condition called non-obstructive hypertrophic cardiomyopathy. An approval for this indication could potentially double the pool of patients Myqorzo serves today.